Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to develop a new national autism strategy.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Autism Act 2009 places a duty on my Rt Hon. Friend, the Secretary of State for Health and Social Care, to consult on, publish, and keep under review a national strategy for meeting the needs of autistic adults in England. My Rt Hon. Friend may choose to revise the strategy, and if so, must publish it as revised.
On 23 January 2026, we published our response to the House of Lords Autism Act 2009 Inquiry Committee’s report Time to deliver: The Autism Act 2009 and the new autism strategy. We are carefully considering the report’s recommendations, as well as our approach to developing a new national autism strategy and will set out a position in due course. The current strategy will remain in effect until a revised strategy is published.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what proposals they intend to take forward in the 10 Year Health Plan for England in relation to services for autistic people.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan sets out to make the National Health Service fit for the future, by delivering three big shifts, from hospital to care in community, from analogue to digital, and from sickness to prevention. The plan will help to address health inequalities for disabled and autistic people by improving access to care, delivering care closer to home, and supporting the development of holistic care plans for those whose needs may require support from multiple health and care providers. We want autistic people’s access to, and experience of, healthcare services to be equitable, effective, and responsive to their needs.
The plan sets out the core principle of early intervention and support, including without the need for diagnosis, including specifically for children and young people, such as those with special educational needs and disabilities (SEND). It is clear about the importance of health services working in partnership with education settings and providing children and young people with early intervention and support to avoid needs escalating, where possible, building on learning from programmes such as Early Language Support for Every Child. We will set out our proposals for SEND reform in the upcoming Schools White Paper.
NHS England continues to support local systems to use a national framework and operational guidance to deliver improved outcomes in all-age autism assessment pathways. It has published national guidance on meeting the needs of autistic adults in mental health services and, to address physical health inequalities, is currently testing a combined health check in primary care for autistic people, those with a severe mental health condition and/or those people with a learning disability.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, in the light of reports about the pricing structure of weight-loss medications used in the NHS, (1) what discussions they have had with Novo Nordisk and Eli Lilly, and (2) what steps they are taking to ensure that costs do not exacerbate regional inequalities in access to treatment.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Commercial access agreements, including confidential discounts, are negotiated to secure affordability and value for money for the National Health Service, and to enable access to clinically effective treatments that may not otherwise meet cost effectiveness thresholds at list price. As is standard across NHS medicines commissioning, the specific terms of commercial agreements remain confidential to protect the NHS’s negotiating position and to ensure best value for public funds.
NHS England, alongside the Department and the National Institute for Health and Care Excellence, routinely engages with pharmaceutical companies, including Novo Nordisk and Eli Lilly, through standard market access and appraisal processes, and commercial and supply discussions following NICE recommendations, and ongoing dialogue on implementation, demand management, and system readiness. NHS England does not comment publicly on the detail of individual commercial negotiations.
For weight management medicines, NHS England is supporting implementation via a phased and prioritised rollout approach. Prioritising populations with the greatest clinical need aligns with NHS objectives to reduce health inequalities.
NHS England is working with regions and integrated care boards to support consistent implementation of national policy, and to address unwarranted variation through guidance, oversight, and data monitoring. These approaches are designed to ensure that cost pressures do not drive postcode-based inequities, while enabling the safe and sustainable introduction of new treatments at scale.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they plan to take to increase transparency around commercial pricing agreements for new weight-loss medications within the NHS, including how pricing decisions reflect anticipated long-term clinical and economic outcomes.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Commercial access agreements, including confidential discounts, are negotiated to secure affordability and value for money for the National Health Service, and to enable access to clinically effective treatments that may not otherwise meet cost effectiveness thresholds at list price. As is standard across NHS medicines commissioning, the specific terms of commercial agreements remain confidential to protect the NHS’s negotiating position and to ensure best value for public funds.
NHS England, alongside the Department and the National Institute for Health and Care Excellence, routinely engages with pharmaceutical companies, including Novo Nordisk and Eli Lilly, through standard market access and appraisal processes, and commercial and supply discussions following NICE recommendations, and ongoing dialogue on implementation, demand management, and system readiness. NHS England does not comment publicly on the detail of individual commercial negotiations.
For weight management medicines, NHS England is supporting implementation via a phased and prioritised rollout approach. Prioritising populations with the greatest clinical need aligns with NHS objectives to reduce health inequalities.
NHS England is working with regions and integrated care boards to support consistent implementation of national policy, and to address unwarranted variation through guidance, oversight, and data monitoring. These approaches are designed to ensure that cost pressures do not drive postcode-based inequities, while enabling the safe and sustainable introduction of new treatments at scale.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to develop a long-term strategy alongside medical professionals to ensure sustainable funding for obesity services, including prevention, behavioural and psychological programmes, and alongside clinical treatments.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service and local government provide a range of obesity services, from universal prevention initiatives to targeted interventions, including behaviour change programmes, digital tools and apps, and specialist services for people living with severe obesity and related conditions. These services support individuals at every stage to achieve and maintain a healthier weight.
Commissioning and funding decisions for obesity services are made locally by local authorities and NHS organisations in line with assessed population needs and available budgets. The Department works with these partners and NHS England to provide national policy direction, to support effective and sustainable service models and to introduce digital behavioural programmes.
NHS England is supporting integrated care boards (ICBs) to deliver a phased roll‑out of tirzepatide for the treatment of obesity. They have provided funding and guidance to ICBs and established a national wraparound support service for patients receiving these treatments, covering diet, physical activity, and behaviour change.
As set out in our 10-Year Health Plan for England, we are taking decisive action on the obesity crisis, including restricting junk food advertising to children, and setting healthy sales reporting and targets for large food businesses.
Whilst we recognise that prevention will always be better than a cure, we also need to support those already living with obesity. We have committed to doubling the number of people able to access the NHS Digital Weight Management Programme and to expand access to the newest obesity medicines.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 5 January (HL13176), what safeguards they plan to put in place to ensure that integrated care boards are subject to proper scrutiny, particularly in relation to the incorporation of patient engagement work into the commissioning of services.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Integrated care boards currently have a statutory duty in relation to public involvement and consultation and are subject to an annual assessment by NHS England of their functions.
The abolition of Healthwatch England and Local HealthWatch arrangements will require primary legislation and is subject to the will of Parliament.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of adjusting the National Institute for Health and Care Excellence cost-effectiveness thresholds for highly specialised technology in line with the new single technology appraisal cost-effectiveness thresholds due to come into effect from April.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.
The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.
There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of increasing the National Institute for Health and Care Excellence highly specialised technology cost-effectiveness threshold on patient access to rare disease medicines.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.
The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.
There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what their rationale is for increasing the National Institute for Health and Care Excellence (NICE) cost-effectiveness thresholds for assessing new medicines to £25–30,000 per quality-adjusted life year; and whether they plan to apply the same proportionate increases to the NICE cost-effectiveness thresholds for highly specialised technologies.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.
The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.
There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what discussions they have had with Healthwatch England about making public comments regarding the Government's decision to transfer its current role to the proposed new patient experience directorate in the Department of Health and Social Care.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government has accepted the recommendations of Dr Penny Dash’s Review of patient safety across the health and care landscape and confirmed in its 10-Year Health Plan for England that the strategic functions of Healthwatch England will transfer to a new patient experience directorate within the Department. This change is intended to strengthen the role of patient voice by embedding it at the centre of a reformed Department.
The Department continues to engage with Healthwatch England as this work progresses. Discussions with Healthwatch England have not included the making of public comments about the transfer of Healthwatch England functions to the proposed patient experience directorate.